Future oncologyPub Date : 2026-08-01Epub Date: 2026-08-19DOI: 10.1080/14796694.2026.2711519
Leo Mascarenhas, Christopher Ollis, Yuvraj Singh, Linet Menachery, Domnita-Ileana Burcoveanu, Esther De La Cuesta, Cornelis M van Tilburg, Theodore W Laetsch
{"title":"Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary.","authors":"Leo Mascarenhas, Christopher Ollis, Yuvraj Singh, Linet Menachery, Domnita-Ileana Burcoveanu, Esther De La Cuesta, Cornelis M van Tilburg, Theodore W Laetsch","doi":"10.1080/14796694.2026.2711519","DOIUrl":"10.1080/14796694.2026.2711519","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2233-2242"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2026-08-01Epub Date: 2026-07-14DOI: 10.1080/14796694.2026.2698699
Carlyn Rose Tan, Lucio Gordan, Joshua Richter, Rachel DiLeo, Prerna Mewawalla, Sarah Larson, Faith Davies, David Oveisi, Niodita Gupta-Werner, Rohan Medhekar, Xin Yin, Annelore Cortoos, Marjohn Armoon, Philippe Thompson-Leduc, Alvi Rahman, Anabelle Tardif-Samson, Claire Vanden Eynde, John Reitan, Gary Milkovich, Joseph Bubalo, Adam Forman, Baylee Bryan, Douglas Sborov, Shuchita Kaila, Saad Usmani
{"title":"Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.","authors":"Carlyn Rose Tan, Lucio Gordan, Joshua Richter, Rachel DiLeo, Prerna Mewawalla, Sarah Larson, Faith Davies, David Oveisi, Niodita Gupta-Werner, Rohan Medhekar, Xin Yin, Annelore Cortoos, Marjohn Armoon, Philippe Thompson-Leduc, Alvi Rahman, Anabelle Tardif-Samson, Claire Vanden Eynde, John Reitan, Gary Milkovich, Joseph Bubalo, Adam Forman, Baylee Bryan, Douglas Sborov, Shuchita Kaila, Saad Usmani","doi":"10.1080/14796694.2026.2698699","DOIUrl":"10.1080/14796694.2026.2698699","url":null,"abstract":"<p><strong>Background: </strong>Frontline (1L) treatment for transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM) has shifted from triplet (e.g. bortezomib [V], lenalidomide [R], dexamethasone [d]) to quadruplet (e.g. daratumumab with VRd [DVRd]) regimens, based on improved efficacy demonstrated in pivotal trials. This real-world study compared progression-free survival (PFS) in TE patients with NDMM treated with DVRd plus DR or R maintenance (DVRd-DR/R) versus VRd plus R maintenance (VRd-R).</p><p><strong>Methods: </strong>Adult TE patients with NDMM who initiated DVRd-DR/R or VRd-R between 1 January 2020 and 30 June 2022 were identified through a retrospective chart review at 10 US sites. PFS was assessed using Kaplan-Meier analyses and propensity score-weighted hazard ratios (HR) were estimated using Cox regression.</p><p><strong>Results: </strong>Overall, 137 patients received DVRd-DR/R and 86 received VRd-R. Over a median follow-up of 26.7 and 39.8 months among the DVRd-DR/R and VRd-R cohorts, respectively, 11 (9.1%) and 32 (29.7%) patients experienced disease progression or death. Median PFS was not reached in either cohort. DVRd-DR/R versus VRd-R was associated with 63% lower risk of disease progression or death (weighted HR: 0.37, 95% confidence interval: 0.17-0.80, <i>p </i>= 0.006).</p><p><strong>Conclusion: </strong>Findings aligned with pivotal trials, demonstrating the significant PFS benefit of 1L DVRd over VRd and supporting its real-world use for TE NDMM.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2169-2177"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2026-08-01Epub Date: 2026-10-10DOI: 10.1080/14796694.2026.2695213
Kim Newcomer, Julie Clauer, Khadijah Ameen, Andrea Incudine, Amy Mulvey, Kathy Steinberg, Jeneth Aquino, Ashley Geiger, Scott Campbell, Ashley Calabrese, Mohamedtaki Tejani, Manish Shah
{"title":"Patient experiences and unmet needs in diagnosis and treatment of metastatic colorectal cancer: results of a US survey.","authors":"Kim Newcomer, Julie Clauer, Khadijah Ameen, Andrea Incudine, Amy Mulvey, Kathy Steinberg, Jeneth Aquino, Ashley Geiger, Scott Campbell, Ashley Calabrese, Mohamedtaki Tejani, Manish Shah","doi":"10.1080/14796694.2026.2695213","DOIUrl":"10.1080/14796694.2026.2695213","url":null,"abstract":"<p><strong>Background: </strong>Metastatic colorectal cancer (mCRC) can impact patients beyond their physical health. We conducted a survey to evaluate patient perspectives on care and treatment experience.</p><p><strong>Methods: </strong>The survey was conducted by The Harris Poll in the United States. Adults with mCRC were recruited via online panels and patient advocacy groups. Sampling precision was measured via a Bayesian credible interval; data were accurate to within 5.3% points (95% confidence level).</p><p><strong>Results: </strong>Of the 344 respondents, 46% identified as non-Hispanic White, 25% as non-Hispanic Black/African American, and 22% as Hispanic; the mean age was 56 years. Overall, 31% reported that their mCRC diagnosis was delayed, with 83% wishing more information had been provided by their health-care provider at diagnosis. Mental health resources were difficult to access for 53% of the respondents and 88% experienced financial impacts because of their mCRC diagnosis. Furthermore, 49% reported negative impacts from health inequities affecting their care. Overall, 67% of the respondents wished for more power in treatment decision-making.</p><p><strong>Conclusions: </strong>The survey highlights key unmet medical and non-medical patient needs in mCRC care. Access to informational resources, including for financial assistance, and a greater emphasis on shared treatment decision-making would help patients feel valued and improve their mCRC experience.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2445-2456"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2026-08-01Epub Date: 2026-07-30DOI: 10.1080/14796694.2026.2705061
Jennifer R Brown, Talha Munir, Andrew H Lipsky, Swetha Challagulla, David Campbell, Keri Yang, Qianhong Fu, Wassim Aldairy, Rhys Williams, Constantine S Tam
{"title":"Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States.","authors":"Jennifer R Brown, Talha Munir, Andrew H Lipsky, Swetha Challagulla, David Campbell, Keri Yang, Qianhong Fu, Wassim Aldairy, Rhys Williams, Constantine S Tam","doi":"10.1080/14796694.2026.2705061","DOIUrl":"10.1080/14796694.2026.2705061","url":null,"abstract":"<p><strong>Background: </strong>In the absence of real-world comparative studies of cardiac death risk, this study estimates the potential reduction in cardiac mortality associated with treating chronic lymphocytic leukemia (CLL) patients with zanubrutinib instead of ibrutinib in first-line (1L) or second-line or later (2L+) in the United States (US).</p><p><strong>Methods: </strong>Number needed to treat (NNT) for incremental cardiac death with ibrutinib versus zanubrutinib was applied to real-world ibrutinib utilization from Symphony over 5 years (2020-2024). Primary analysis utilized head-to-head cardiac death risks from ALPINE (2L+). An exploratory 1L analysis utilized indirect comparisons from SEQUOIA and RESONATE-2. Sensitivity analyses assessed cardiac death risk with 10+ years of ibrutinib utilization (2014-2024).</p><p><strong>Results: </strong>In 2L+ CLL, NNT for incremental cardiac death was 54 patients. Based on real-world ibrutinib use, 81 cardiac deaths could potentially have been avoided with zanubrutinib over 5 years. The exploratory 1L CLL NNT per cardiac death was 46, corresponding to 140 potentially avoidable deaths if patients were treated with zanubrutinib. Over a 10+ year period, the number of potentially avoidable deaths increased to 318 (2L+) and 489 (1L).</p><p><strong>Conclusions: </strong>The NNT model suggests substantial cardiac death reductions if zanubrutinib were utilized instead of ibrutinib for CLL treatment in US practice.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2271-2278"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2026-08-01Epub Date: 2026-07-29DOI: 10.1080/14796694.2026.2707796
Arun A Azad, Bhavik J Pandya, Hemant Singh Bhadauria, Erhan Berrak, Vagia Daki, Paulo Martins, Janet Kim, Alexis Serikoff, Gianluca Baio, Andrew J Armstrong
{"title":"Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.","authors":"Arun A Azad, Bhavik J Pandya, Hemant Singh Bhadauria, Erhan Berrak, Vagia Daki, Paulo Martins, Janet Kim, Alexis Serikoff, Gianluca Baio, Andrew J Armstrong","doi":"10.1080/14796694.2026.2707796","DOIUrl":"10.1080/14796694.2026.2707796","url":null,"abstract":"<p><strong>Aims: </strong>To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus apalutamide + ADT in metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC).</p><p><strong>Patients and methods: </strong>Individual patient data from patients with ≥1 confirmed bone metastasis in ARCHES (NCT02677896; enzalutamide + ADT vs placebo + ADT; <i>n</i> = 971) were adjusted to match baseline characteristics of patients in TITAN (NCT02489318; apalutamide + ADT vs placebo + ADT; <i>N</i> = 1052). Overall survival (OS), radiographic progression-free survival (rPFS), and time to prostate-specific antigen progression (TTPP) were assessed using Cox regression with placebo + ADT as the common comparator. Hazard ratios (HRs) were reported with apalutamide as the reference.</p><p><strong>Results: </strong>This MAIC suggested similar estimated efficacy between enzalutamide and apalutamide for OS (HR: 0.81, 95% confidence interval [CI]: 0.58-1.15) and TTPP (HR: 0.65, 95% CI: 0.41-1.03). Patients treated with enzalutamide + ADT had improved rPFS versus those treated with apalutamide + ADT (HR: 0.66, 95% CI: 0.45-0.98), but differences were not significant in sensitivity analyses aligning assessment methods.</p><p><strong>Conclusions: </strong>This analysis suggested broadly similar efficacy between enzalutamide and apalutamide in patients with mHSPC. Findings should be interpreted in the context of inherent MAIC limitations.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2287-2298"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148601978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).","authors":"Francesco Passiglia, Eugenia Priedane, Silvy Mardiguian, Mariana Farraia, Anuja Pandey, Pragya Shukla, Caroline von Wilamowitz-Moellendorff, Simone Rivolo, Ariadna Mendoza-Naranjo, Shiangjiin Leaw, Kirsha Naicker, Yu Wang, Xiao Lin, Venediktos Kapetanakis","doi":"10.1080/14796694.2026.2696934","DOIUrl":"10.1080/14796694.2026.2696934","url":null,"abstract":"<p><strong>Background: </strong>Tislelizumab was evaluated in randomized controlled trials (RCTs) for non-small cell lung cancer (NSCLC) (RATIONALE-315, RATIONALE-303) and extensive-stage small cell lung cancer (ES-SCLC) (RATIONALE-312), primarily in Asian populations. We assessed the transportability of clinical findings from these RCTs to European patients.</p><p><strong>Methods: </strong>Targeted literature reviews (TLRs) identified real world-evidence (RWE), RCTs, and treatment effect modifiers in perioperative NSCLC, second-line or later (2L+) NSCLC, and first-line (1L) ES-SCLC. Relevant RWE studies were selected to define the target European-like populations. Outcome regression models used RATIONALE individual patient data to predict relative treatment effect of tislelizumab vs. comparators in European populations.</p><p><strong>Results: </strong>Event-free survival (HR 0.56), major pathological response (OR 7.49) and pathological complete response (OR 11.54) from RATIONALE-315 were similar to those predicted for the base case European target perioperative NSCLC population (EFS HR 0.57; MPR OR 3.39; PCR OR 8.95). Predicted overall survival and progression-free survival for 2L+ NSCLC and for 1L ES-SCLC were similar to RATIONALE-303 and RATIONALE-312, respectively.</p><p><strong>Conclusion: </strong>The efficacy of tislelizumab observed in the RATIONALE trials explored in this analysis is transportable, subject to the specified assumptions, to European patients in the setting of perioperative NSCLC, 2L+ NSCLC, and 1L ES-SCLC, consistently favoring tislelizumab over control.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2143-2154"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2026-08-01Epub Date: 2026-08-08DOI: 10.1080/14796694.2026.2715869
Howard Thom, Martin Boegemann, Neal Shore
{"title":"Commentary on \"matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC\".","authors":"Howard Thom, Martin Boegemann, Neal Shore","doi":"10.1080/14796694.2026.2715869","DOIUrl":"10.1080/14796694.2026.2715869","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2367-2369"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2026-08-01Epub Date: 2026-09-22DOI: 10.1080/14796694.2026.2721180
Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi, Paolo A Ascierto, Jun Guo, Ahmad A Tarhini, Sunandana Chandra, Eva Muñoz-Couselo, Michele Del Vecchio, Andreia Cristina de Melo, Margaret Callahan, Helen Gogas, Reinhard Dummer, Dirk Schadendorf, Peter Koelblinger, Gaelle Quereux, Ioannis Thomas, Jia Xin Yu, Andrew Fisher, Bonnie Wang, Patrick Djidel, Armand Chouzy, Mark Semaan, Bohang Chen, Alicia M Y Cheong, Hussein A Tawbi
{"title":"Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery.","authors":"Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi, Paolo A Ascierto, Jun Guo, Ahmad A Tarhini, Sunandana Chandra, Eva Muñoz-Couselo, Michele Del Vecchio, Andreia Cristina de Melo, Margaret Callahan, Helen Gogas, Reinhard Dummer, Dirk Schadendorf, Peter Koelblinger, Gaelle Quereux, Ioannis Thomas, Jia Xin Yu, Andrew Fisher, Bonnie Wang, Patrick Djidel, Armand Chouzy, Mark Semaan, Bohang Chen, Alicia M Y Cheong, Hussein A Tawbi","doi":"10.1080/14796694.2026.2721180","DOIUrl":"10.1080/14796694.2026.2721180","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2435-2444"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time.","authors":"Eisaku Miyauchi, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Nobuyuki Katakami, Masahide Oki, Takashi Kijima, Kenichi Chikamori, Kazumi Nishino, Takuma Arai, Kenichiro Ieda, Akihiko Gemma","doi":"10.1080/14796694.2026.2706981","DOIUrl":"10.1080/14796694.2026.2706981","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2371-2383"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2026-08-01Epub Date: 2026-07-27DOI: 10.1080/14796694.2026.2696928
Jens Bedke, Anthony Eccleston, Mia Unsworth, Julia Brinkmann, Jane Chang, Abin Koshy, Laure Manuel, Jacob Skilling, Emilia Biondi, Elliott Brown, Caitlin Ford, Gary Steinberg, Yair Lotan, Yohann Loriot, Oscar Rodriguez Faba
{"title":"Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.","authors":"Jens Bedke, Anthony Eccleston, Mia Unsworth, Julia Brinkmann, Jane Chang, Abin Koshy, Laure Manuel, Jacob Skilling, Emilia Biondi, Elliott Brown, Caitlin Ford, Gary Steinberg, Yair Lotan, Yohann Loriot, Oscar Rodriguez Faba","doi":"10.1080/14796694.2026.2696928","DOIUrl":"10.1080/14796694.2026.2696928","url":null,"abstract":"<p><strong>Introduction: </strong>Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is particularly prevalent in men. Guidelines stratify patients into risk categories based on disease characteristics as patients often recur or progress to muscle-invasive disease. Most guidelines recommend transurethral resection of bladder tumor (TURBT) followed by up to 3 years of Bacillus Calmette-Guerin (BCG) therapy for high-risk (HR) patients. For very HR patients or those who recur after BCG, radical cystectomy (RC) is recommended. This study aimed to describe the profile of individuals with HR-NMIBC, alongside treatment patterns and outcomes across Europe, North America, and Japan.</p><p><strong>Methods: </strong>Data were extracted from the Adelphi Disease Specific Program for 1,864 patients initially diagnosed with HR-NMIBC and 273 with very HR-NMIBC.</p><p><strong>Results: </strong>First-line treatment was mainly intravesical BCG, however, less than half of patients received the guideline recommended maintenance BCG and none received RC. Second-line treatment options were similar to first-line, with RC usage still rare.</p><p><strong>Conclusion: </strong>While TURBT+BCG was shown to be the current standard of care, the underutilization of full guideline recommended treatment alongside the relatively high number of recurrences highlights the need for novel therapeutic approaches, either in combination with BCG therapy, or as alternative first-line treatments.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2155-2168"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
